Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04584983 · ClinicalTrials.gov registry record · Phase 2
Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration
A Phase 2 study of Bilirubin Encephalopathy, sponsored by The University of Texas Health Science Center, Houston.
- Active
- Registry status
- Phase 2
- Development phase
- 134
- Enrollment target
- 1
- Study location
NCT04584983: Active Phase 2 study of Bilirubin Encephalopathy, sponsored by The University of Texas Health Science Center, Houston.
NCT04584983 is a Phase 2 study of Bilirubin Encephalopathy that is active but no longer recruiting, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 134 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04584983, a Phase 2 study of Bilirubin Encephalopathy, is active but no longer recruiting, sponsored by The University of Texas Health Science Center, Houston.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 134 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effect of usual versus reduced lipid intake on unbound bilirubin levels, brainstem auditory evoked responses, and neurodevelopmental outcome at 2 years in extremely preterm infants.
Conditions Studied
Interventions
- DRUG usual prescribed intralipid (UL) regimen
- DRUG restricted prescribed intralipid (RL) regimen
Study Locations (1)
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2021-02-11 |
| Est. Completion | 2026-06-14 |
| Phase | Phase 2 |
What the registry record for NCT04584983 still lists
NCT04584983 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Bilirubin Encephalopathy appearing as the primary indexed condition, and to 2 interventions - of which usual prescribed intralipid (UL) regimen is the first listed.
NCT04584983 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04584983 about?
NCT04584983 is a clinical study titled "Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration". The purpose of this study is to evaluate the effect of usual versus reduced lipid intake on unbound bilirubin levels, brainstem auditory evoked responses, and neurodevelopmental outcome at 2 years in extremely preterm infants.
What is the current status of trial NCT04584983?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 134 participants. The study started on 2021-02-11. Estimated completion is 2026-06-14.
What conditions does trial NCT04584983 study?
This clinical trial studies the following conditions: Bilirubin Encephalopathy.
What interventions are being tested in trial NCT04584983?
The interventions under investigation include: usual prescribed intralipid (UL) regimen (DRUG), restricted prescribed intralipid (RL) regimen (DRUG).
Who is sponsoring clinical trial NCT04584983?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04584983 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04584983's enrollment target sits among peer trials
134 537th of 2000 higher than 1,463 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI